-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
While vaccine and testing companies have paid dividends in recent years due to the pandemic, the track is slowly closing
AstraZeneca's adenovirus-based COVID vaccine Vaxzevria has been in the
CEO Pascal Soriot said perhaps the company would consider exiting the vaccine business
This is not an impulsive idea
The uncertainty of the company's vaccine development also manifested itself in the creation of a new division for pandemic treatment at the time, including vaccines and antibodies, while considering whether the division would be set up as a separate company
Judging from the financial report for the second quarter of this year, the profitable part of AstraZeneca did not include the pipeline
And that's not the first company
Information reference:
Information reference: